Lantern Pharma (LTRN) announced that the first patient has been dosed – as part of the expansion cohort – in Japan for its Phase 2 Harmonic clinical trial evaluating LP-300 in never-smoker patients with non-small cell lung cancer, or NSCLC, who have progressed after receiving treatment with tyrosine kinase inhibitors, or TKIs.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks